Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties

Journal of Cardiovascular Pharmacology

Volumn 9, Issue 3, 1987, Pages 317-327

  Sponer, G ^a   Bartsch, W ^a   Strein, K ^a   Muller Beckmann B ^a   Bohm E ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Carvedilol; Experimental models; Hypotensive activity; Vasodilatation; Blockade

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIHYDRALAZINE; ISOPRENALINE; LABETALOL; PINDOLOL; PRIZIDILOL; PROPRANOLOL;

ANIMAL EXPERIMENT; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOG; DOSE RESPONSE; DRUG EFFICACY; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; RABBIT; RAT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; DOGS; HEMODYNAMIC PROCESSES; ISOPROTERENOL; MYOCARDIAL CONTRACTION; PROPANOLAMINES; RABBITS; RATS; SYMPATHOMIMETICS; VASODILATOR AGENTS;

EID: 0023130760     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-198703000-00009     Document Type: Article

References (30)

1. De Quattro V, Hamad R. The role of stress and the sympathetic nervous system in hypertension and ischemic heart disease. Advantages of therapy with β-receptor blockers. Clin Exp Hypertens 1985;17:907-32.
2. Warren SG, Brewer DL, Orgain ES. Long term propranolol therapy for angina pectoris. Am J Cardiol 1976;37:420-6.
3. Norwegian Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
4. Man in't Veld AJ, Schalekamp MADH. Haemodynamic consequences of intrinsic sympathomimetic activity and cardio-selectivity in β-blocker therapy for hypertension. Ear Heart J 1983;4(suppl D):31-41.
5. Lund-Johansen P. Central haemodynamic effects of β-blockers in hypertension. A comparison between atenolol. metoprolol, timolol, penbutolol, alprenolol, pindolol and bunitolol. Ear Heart J 1983:4(suppl D):1-12.
6. Tarazi RC, Dustan HP. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol 1972;29:633-40.
7. Birkenhäger WH, DeLeeuw PW. Adrenergic vasoconstriction as a cause of inadequate hypotensive response to beta-adrenergic blockade. Hypertension 1983;5(suppl 111):31-5.
8. Sannerstedt R, Stenberg J, Vedin A, Wilhelmsson C, Werkö L. Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment. Am J Cardiol 1972;29:718-23.
9. Zacest R, Gilmore E, Koch-Weser J. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 1972;286:617-22.
10. Klein HO, Berger HJ. Synergistic actions of nitrate and β-adrenergic blocking agents in the therapy of angina pectoris. Cardiology 1973:58:313-25.
11. Russek HJ. Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol 1968:21:44-9.
12. McAreavey LE. Ramsay LE, Latham L, Lorimer AR, McLaren D. Reid JL, Robertson JIS. Robertson MP. Weir RJ. The "third drug" trial: A comparative study of antihypertensive agents to treatment when blood pressure is uncontrolled by a beta-blocker plus thiazide diuretic. J Hypertens 1983;1(suppl 2): 116-9.
13. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-58.
14. Furchgott RF, Bhadrakom S. Reaction of strips of rabbit aorta to epinephrine, isopreterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther 1953:108:129-43.
15. Armah IB, Hufnagel A, Jacobitz P. Vasodilating β-receptor antagonists: comparison of the pharmacological actions of labetalol, prizidilol and carvedilol (submitted for publication).
16. Eggertsen R, Sivertsson R, Andren L, Hansson L. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 1984:2:529-34.
17. Eggertsen R. Beta adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress. Acta Med Scand 1984;689(suppl):1-46.
18. Leonetti G, Terzoli L, Sala C, Bianchini C. Zanchetti A. Dose response curve and time course of the antihypertensive effect of SKF 92.657, a β-receptor blocking and vasodilating compound. Clin Sci 1980;59(suppl):461s-3s.
19. Dage RC, Cheng HC, Woodward JK. Cardiovascular properties of medroxalol. a new antihypertensive drug. J Car-diovasc Pharmacol 1981;3:299-315.
20. Deitchman D. Perhach JL, Snyder RW. Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anaesthetized dogs and rats. Ear J Pharmacol 1980:61:263-77.
21. Deitchman D, Byrne JE, Snyder RW. Cardiovascular effects of bucindolol (MJ 13105) in conscious dogs. Arch Int Phar-macodyn Ther 1980;247:76-88.
22. Deitchman D, La Budde JA. Seidehamel RJ. Bucindolol. In: Scriabine A (ed): New drags annual: cardiovascular drugs. New York: Raven Press, 1983:1-18.
23. Oates HF. Stoker LM, Stokes GS. Studies in the rat with bucindolol, a new antihypertensive agent with beta-adrenoceptor blocking properties. Arch Int Pltarmacodyn Ther 1981;251:95-102.
24. Pittner H. Hämodynamische Wirkungen von Celiprolol und anderen β-Rezeptoren-Blockern an narkotisierten Hunden. Arzneim Forsch 1983;33:26-9.
25. Koch-Weser J. Correlation of pathophysiology and pharmacotherapy in primary hypertension. Am J Cardiol 1973;32:499-510.
26. Koch-Weser J. Vasodilator drugs in the treatment of hypertension. Arch Intern Med 1974;133:1017-27.
27. Brittain RT, Drew GM, Levy GP. The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982:77:105-14.
28. Kennedy I, Levy GP. Combined alpha- and β-adrenoceptor blocking drug AH 5158: Further studies on alpha-adreno-ceptor blockade in anaesthetized animals. Br J Pharmacol 1975;53:585-92.
29. Meyer-Sabellek WA, Schulte K-L. Thiede HM. Götzen R. Acute hypotensive response of a new antihypertensive drug (BM 14.190) in essential hypertensive patients. J Hypertens 1983;1(suppl 2):351-2.
30. Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM 14.190) a new beta-blocking drug with vasodilating properties in exercise induced ischemia. Am J Cardiol 1985;56:35-40.